Evidence map›Paper›PMID 34796023›Full record

ReviewSovremennye tekhnologii v meditsine2021

Molecular Mechanisms of Proteins - Targets for SARS-CoV-2 (Review).

A V Morgun, V V Salmin, E B Boytsova, O L Lopatina, A B Salmina

Open access · diamondAbstract readReview
In one paragraph

Review in Sovremennye tekhnologii v meditsine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. ACE2: Friend or Foe in Post-COVID-19 Neurodegeneration?International journal of molecular sciences · 2025
    Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

A V MorgunAssociate Professor, Department of Pediatrics; Krasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky, 1 Partizana Zheleznyaka St., Krasnoyarsk, 660022, Russia.
V V SalminProfessor, Head of the Department of Medical and Biological Physics; Krasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky, 1 Partizana Zheleznyaka St., Krasnoyarsk, 660022, Russia.
E B BoytsovaInfectious Disease Physician; Regional Clinical Hospital, 3a Partizana Zheleznyaka St., Krasnoyarsk, 660022, Russia.
O L LopatinaProfessor, Department of Biological, Medical, Pharmaceutical and Toxicological Chemistry; Krasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky, 1 Partizana Zheleznyaka St., Krasnoyarsk, 660022, Russia.
A B SalminaProfessor, Head of the Department of Biological, Medical, Pharmaceutical and Toxicological Chemistry Krasnoyarsk State Medical University named after Prof. V.F. Voino-Yasenetsky, 1 Partizana Zheleznyaka St., Krasnoyarsk, 660022, Russia.
Krasnoyarsk State Medical University · RUKrasnoyarsk Regional Clinical Hospital · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rapidly accumulating information about the new coronavirus infection and the ambiguous results obtained by various authors necessitate further research aiming at prevention and treatment of this disease. At the moment, there is convincing evidence that the pathogen affects not only the respiratory but also the central nervous system (CNS). Results: By analyzing the literature, we provide evidence that the brain is targeted by this virus. SARS-CoV-2 enters the body with the help of the target proteins: angiotensin-converting enzyme 2 (ACE2) and associated serine protease TMPRSS2 of the nasal epithelium. Brain damage develops before the onset of pulmonary symptoms. The virus spreads through the brain tissue into the piriform cortex, basal ganglia, midbrain, and hypothalamus. Later, the substantia nigra of the midbrain, amygdala, hippocampus, and cerebellum become affected. Massive death of neurons, astrogliosis and activation of microglia develop at the next stage of the disease. By day 4, an excessive production of proinflammatory cytokines in the brain, local neuroinflammation, breakdown of the blood-brain barrier, and impaired neuroplasticity are detected. These changes imply the involvement of a vascular component driven by excessive activity of matrix metalloproteinases, mediated by CD147. The main players in the pathogenesis of COVID-19 in the brain are products of angiotensin II (AT II) metabolism, largely angiotensin 1-7 (AT 1-7) and angiotensin IV (AT IV). There are conflicting data regarding their role in damage to the CNS in various diseases, including the coronavirus infection.The second participant in the pathogenesis of brain damage in COVID-19 is CD147 - the inducer of extracellular matrix metalloproteinases. This molecule is expressed on the endothelial cells of cerebral microvessels, as well as on leukocytes present in the brain during neuroinflammation. The CD147 molecule plays a significant role in maintaining the structural and functional integrity of the blood-brain barrier by controlling the basal membrane permeability and by mediating the astrocyte-endothelial interactions. Via the above mechanisms, an exposure to SARS-CoV-2 leads to direct damage to the neurovascular unit of the brain.

Indexed as

Angiotensin-Converting Enzyme 2Angiotensin IAngiotensin IIAstrocytesBasiginBrainCOVID-19HumansPeptide FragmentsSARS-CoV-2Serine EndopeptidasesACE2 protein, humanAngiotensin-Converting Enzyme 2Angiotensin Iangiotensin I (1-7)Angiotensin IIangiotensin II, des-Asp(1)-des-Arg(2)-Ile(5)-BasiginBSG protein, humanPeptide FragmentsSerine EndopeptidasesTMPRSS2 protein, humanACE2blood-brain barrierbrain damage in COVID-19CD147coronavirus infectionneuroinflammationSARS-CoV-2

Identifiers

PMID34796023
PMCPMC8596231
OpenAlexW3115472936

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.